1. Home
  2. AKBA vs LYTS Comparison

AKBA vs LYTS Comparison

Compare AKBA & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.48

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Logo LSI Industries Inc.

LYTS

LSI Industries Inc.

HOLD

Current Price

$18.08

Market Cap

700.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
LYTS
Founded
2007
1976
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building Products
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
729.1M
700.9M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
AKBA
LYTS
Price
$1.48
$18.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
$6.25
$27.50
AVG Volume (30 Days)
5.0M
196.9K
Earning Date
11-10-2025
01-22-2026
Dividend Yield
N/A
1.09%
EPS Growth
N/A
2.57
EPS
N/A
0.80
Revenue
$225,071,000.00
$592,531,000.00
Revenue This Year
$52.38
$5.91
Revenue Next Year
$22.45
$8.03
P/E Ratio
N/A
$22.83
Revenue Growth
32.49
22.35
52 Week Low
$1.46
$13.77
52 Week High
$4.08
$25.50

Technical Indicators

Market Signals
Indicator
AKBA
LYTS
Relative Strength Index (RSI) 28.25 35.51
Support Level $1.52 $17.79
Resistance Level $1.63 $18.60
Average True Range (ATR) 0.10 0.56
MACD 0.02 0.10
Stochastic Oscillator 1.15 42.00

Price Performance

Historical Comparison
AKBA
LYTS

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About LYTS LSI Industries Inc.

LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.

Share on Social Networks: